S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
OncLive® On Air
00:00
Safety Signals with Asciminib: Vascular Events
Elias Jabbour highlights a ~5% rate of vasculopathic events with asciminib in short follow-up and advises monitoring.
Play episode from 07:22
Transcript
